Dr Steidl is an Assistant Professor in the Department of Pathology (University of British Columbia) and Experimental Therapeutics (BC Cancer Agency). He is holding an MD degree from the University of Muenster, Germany, and a PhD equivalent degree from University of Witten-Herdecke, Germany. Dr Steidl has expertise in clinical malignant hematology, cytogenetics, molecular genetics, next generation sequencing and functional genomics. Dr Steidl joined the Centre for Lymphoid Cancer at the British Columbia Cancer Agency in 2006. He is currently supervising a translational research laboratory focusing on the pathogenesis of B cell lymphomas. Dr Steidl is most known for his work on biomarkers in Hodgkin lymphoma and discovery of somatic mutations and novel gene fusions in B cell lymphomas. He has authored 47 refereed articles in the field of hematological malignanices and has been an invited speaker at many conferences. He also serves as a member of the Lymphoma Research Foundation’s Panel of Scientific Advisors and the Medical Expert Committee of the Cancer Research Society. Dr Steidl holds research funding as the principle investigator by the Canadian Institutes of Health Research (CIHR), the Leukemia and Lymphoma Society of Canada (LLSC), the Canadian Hematology Society (CHS), the Terry Fox Research Institute (TFRI), the Canadian Cancer Society Research Institute (CCSRI) and is co-investigator on a Genome Canada grant to advance personalized treatments of lymphoid cancer patients. Dr Steidl also holds a career investigator award by the Michael-Smith Foundation for Health Research (MSFHR) and a New Investigator Award by CIHR.